Timothy Hughes


  • 32060 Citations
  • 74 h-Index
1989 …2019
If you made any changes in Pure these will be visible here soon.

Personal profile

Public Profile

Professor Timothy Hughes is the Precision Medicine Theme Leader at SAHMRI and Consultant Haematologist in the Division of Haematology at SA Pathology. He is also the Cancer Council Chair in Cancer Research, Chair of the International Chronic Myeloid Leukemia Foundation (iCMLf) and Fellow of the Australian Academy of Health and Medical Sciences (AAHMS).

Professor Hughes is an international expert in the biology and treatment of leukaemia. He led the establishment of the molecular response criteria that are used world-wide to measure response in chronic myeloid leukaemia (CML) and has led many of the key Global and National trials. His group has successfully developed predictive bioassays and molecular targets that influence the way CML patients are managed world-wide. He has published over 250 papers that have been cited over 40,000 times. 

In October 2017 Professor Hughes was awarded the GSK Award for Research Excellence 2017 for pioneering the use of tyrosine kinase inhibitors (TKIs).

Education/Academic qualification

PhD, Doctor of Medicine , University of New South Wales

… → 1993

Fellowship of the Royal Australasian College of Physicians

… → 1988

Fellowship of the Royal College of Pathologists of Australia

… → 1988

MB BS (Honours), University of New South Wales

… → 1981

External positions

Consultant Haematologist , SA Pathology

Beat Cancer Professor, University of Adelaide

Chair, International CML Foundation

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1989 2019

Bone marrow fibrosis associated with long-term imatinib therapy: Resolution after switching to a second-generation TKI

Shanmuganathan, N., Branford, S., Hughes, T. & Hiwase, D., 12 Feb 2019, In : Blood Advances. 3, 3, p. 370-374 5 p.

Research output: Contribution to journalArticle

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for philadelphia chromosome-positive leukemia

Hughes, T. P., Laneuville, P., Rousselot, P., Snyder, D. S., Rea, D., Shah, N. P., Paar, D., Abruzzese, E., Hochhaus, A., Lipton, J. H. & Cortes, J. E., 2019, In : Haematologica. 104, 1, p. 93-101 9 p.

Research output: Contribution to journalArticle

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia

on behalf of the International CML Foundation Genomics Alliance, 1 Aug 2019, In : Leukemia. 33, 8, p. 1835-1850 16 p.

Research output: Contribution to journalReview article

Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia

Ross, D. M., Pagani, I., Irani, Y., Clarson, J., Gray, T., Dang, Y., McLean, J., Saunders, V., Carne, L., Reynolds, J., Ritchie, D. S., White, D., Branford, S., Hughes, T. & Yong, A., 1 Aug 2019, In : British Journal of Haematology. 186, 3, p. e56-e60

Research output: Contribution to journalLetter

1 Citation (Scopus)

Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission

Shanmuganathan, N., Braley, J. A., Yong, A., Hiwase, D. K., Yeung, D., Ross, D. M., Hughes, T. & Branford, S., 4 Jul 2019, In : Blood. 134, 1, p. 85-89 5 p.

Research output: Contribution to journalLetter